Preliminary results show a 94.5% effectiveness rate for Moderna’s coronavirus vaccine in Phase 3 trials. The company expects to request emergency use authorization from the FDA within a few weeks. Dr. Jon LaPook reports. Source

JOIN NCOV.LINK NEWSLETTER

And get notified everytime we publish a new Important announcements. We will not email you often, unless there are important things that need to get in touch with you, such as added new tools or new domain names.